Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $8.00

Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have been assigned an average recommendation of "Buy" from the eight research firms that are presently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $8.00.

PRQR has been the subject of several research analyst reports. Oppenheimer reduced their price objective on shares of ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. HC Wainwright upped their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday, March 14th. Citigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a report on Monday, March 10th. Evercore ISI began coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 price objective for the company. Finally, Chardan Capital restated a "buy" rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research report on Friday, March 14th.

Institutional Trading of ProQR Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC lifted its stake in ProQR Therapeutics by 699.3% during the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company's stock valued at $121,000 after buying an additional 79,720 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in ProQR Therapeutics by 16.3% during the first quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company's stock valued at $4,368,000 after buying an additional 459,512 shares in the last quarter. Walleye Capital LLC lifted its stake in ProQR Therapeutics by 11.6% during the first quarter. Walleye Capital LLC now owns 503,564 shares of the biopharmaceutical company's stock valued at $670,000 after buying an additional 52,261 shares in the last quarter. Aberdeen Group plc purchased a new stake in ProQR Therapeutics during the first quarter valued at about $2,461,000. Finally, Persistent Asset Partners Ltd purchased a new stake in ProQR Therapeutics during the first quarter valued at about $64,000. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Trading Up 6.7%

PRQR stock traded up $0.12 during trading on Thursday, hitting $1.91. The company had a trading volume of 329,821 shares, compared to its average volume of 639,611. The firm has a market capitalization of $200.96 million, a price-to-earnings ratio of -5.97 and a beta of 0.31. The business has a 50 day moving average of $1.51 and a 200 day moving average of $2.13. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The company had revenue of $4.89 million during the quarter, compared to analyst estimates of $4.90 million. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. As a group, equities analysts predict that ProQR Therapeutics will post -0.31 EPS for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).